Even as the European Commission (EC) and European Medicines Agency (EMA)
approved the new direct-acting antiviral (DAA) daclatasvir to treat
hepatitis C, the international medical humanitarian organization
Médecins Sans Frontières (MSF) has asked the Bristol-Myers Squibb
(inventor of daclatasvir) to ensure that people living with hepatitis C
in low- and middle-income countries can actually access this important
drug, so that it can have the greatest impact on hepatitis C globally in
helping to cure people.
Welcoming the EMA’s approval of
daclatasvir on August 27, 2014, the MSF said that the BMS must rapidly
register daclatasvir in those countries with a high burden of hepatitis
C, especially in those countries with a high prevalence of genotype 3.
It also urged BMS to ensure daclatasvir is affordable in those countries
with a high burden of hepatitis C.